Home
NewsNewsMaven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Maven Clinic, the largest virtual clinic specialising in women’s and family health, has announced an expansion of its Fertility and Family Building program. The update introduces earlier diagnostic lab testing, condition-specific care pathways, and the first integration of FDA-listed ovulation prediction insights from ŌURA into a fertility care platform. These enhancements are designed to provide members with answers earlier in their journey and accelerate the transition to appropriate clinical care. The rollout is scheduled to begin this spring, with additional capabilities continuing to launch throughout 2026.
The expansion addresses significant economic and clinical challenges within the fertility sector, where 70% of employers have reported rising costs over the last three years. Despite 85% of infertility cases having identifiable underlying causes, individuals often spend an average of two years attempting to conceive before seeking professional support. This delay frequently results in unnecessary medical interventions and increased emotional stress.
Kate Ryder, founder and CEO of Maven Clinic, stated: "One of the most costly and least visible drivers of waste in our fertility system is delayed diagnosis, months or years spent trying without information, only to arrive at a clinic already behind. Time lost early becomes dollars spent later, in more aggressive treatment, higher-risk pregnancies, and preventable NICU stays. That's why Maven is building fertility care for the future, a connected system where data follows the member, lab diagnostics and wearable technology integrate, care teams cushion decision-making at every juncture and no family starts their journey already feeling like they're failing."
A key component of the updated Fertility and Family Building program is the integration of diagnostic testing directly into the care model. This includes hormone testing, genetic carrier screening, and foundational fertility panels that are typically ordered later in the process. By identifying issues such as hormonal imbalances or ovulatory disorders sooner, members can enter specialist care with established data, reducing delays and avoiding repeat testing. Results are managed within the Maven platform, allowing for direct consultation with providers to determine next steps. Additionally, the program introduces dedicated support for conditions like PCOS—which affects 10–13% of reproductive-age women, as well as endometriosis and oncofertility, the latter in partnership with Color Health.
The program’s technological foundation is powered by Maven Intelligence, an AI-powered orchestration layer that synthesizes data from lab results, clinical inputs, and wearable devices. As part of this strategy, Maven is the first partner to integrate continuous, clinically validated cycle insights from ŌURA to help members and care teams understand optimal timing for conception or when to adjust treatment pathways. These data-driven improvements have already contributed to measurable outcomes: 30% of members achieve pregnancy without assisted reproductive technology, and employers save an average of $9,600 per birth across fertility and maternity care. Furthermore, 88% of members report being more productive at work during their treatment. Future developments for the Fertility and Family Building experience include deeper connectivity with physical clinic partners and the creation of cohort-based insights to improve treatment adherence and support.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
Mochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
